Prostatype Genomics signs agreement with Cambridge Clinical Laboratories, CCL
-Prostatype® prostate cancer test made available for patients in UK & IrelandToday, Prostatype Genomics is proud to announce an agreement with an ideally suitable partner for our exceptional product, Cambridge Clinical Laboratories, CCL. Since 2005, CCL has been leading in finding and implementing innovative diagnostic and prognostic tools for the benefit of healthcare and patients in the United Kingdom and Ireland. Pursuant to this agreement, CCL will now offer the Prostatype® prostate cancer gene test in their own labs, as well as promoting the test to uro-oncological facilities all